Sept 3 (Reuters) - India’s Cipla (CIPL.NS) said on Thursday its U.S. unit entered an exclusive partnership with China’s Qilu Pharmaceutical to license a biosimilar version of Merck’s (MRK.N) cancer drug Keytruda for the U.S. market.

9 月 3 日（路透社）——印度西普拉（CIPL.NS）週四表示，其美國子公司已與中國齊魯製藥達成獨家合作伙伴關係，獲得默克（MRK.N）抗癌藥物 Keytruda 生物類似藥版本在美國市場的許可權。

Here are more details:

更多細節如下：

Under the agreement, Qilu will handle development, regulatory approvals, manufacturing and supply of QL2107, a biosimilar version of Merck’s Keytruda, while Cipla USA will be responsible for commercialization and sales in the United States.

根據協議，齊魯製藥將負責默克 Keytruda 生物類似藥 QL2107 的開發、監管審批、生產和供應，而西普拉美國公司將負責在美國的商業化和銷售。

QL2107 was developed to offer patients a more affordable treatment option that matches the original cancer therapy’s safety and efficacy profile.

QL2107 的開發旨在為患者提供一種更具負擔能力的治療選擇，其在安全性和療效方面與原研抗癌療法相當。

Cipla said the agreement supports its strategy to expand its oncology-focused biosimilars portfolio, leveraging Qilu’s research and manufacturing capabilities and Cipla’s U.S. commercial network.

西普拉表示，該協議支持其擴大以腫瘤為重點的生物類似藥產品組合的戰略，利用齊魯製藥的研發和生產能力以及西普拉在美國的商業網絡。

Keytruda, until recently the world’s top-selling drug, is used against 20 different kinds of ‌cancerous tumors and ⁠45 types and stages of cancer. Merck is set to lose patent protection for Keytruda in 2028.

Keytruda 直至最近仍是全球最暢銷藥物，用於治療 20 種不同的癌症腫瘤以及 45 種類型和階段的癌症。默克將於 2028 年失去 Keytruda 的專利保護。

推薦閱讀